Gordon J. Freeman is an American immunologist and oncologist at the Dana-Farber Cancer Institute and Harvard Medical School.
Education
editFreeman earned a bachelor's degree in biochemistry and molecular biology from Harvard University. In 1979, he earned a Ph.D. there and then worked as a postdoctoral fellow with Harvey Cantor and Lee Nadler at the Dana-Farber Cancer Institute (DFCI).
Career and research interests
editAs of 2016, he leads a working group at the DFCI and is a professor of internal medicine at Harvard Medical School.[1]
Freeman is concerned with stimulatory and inhibitory signals in the process of the immune response . He was able to significantly clarify the importance of B7-1, B7-2 and other members of the B7 gene family as well as of CD28 and CTLA-4 in T cell activation and of PD-L1 / PD-1 (programmed cell death protein 1) contribute to the inhibition of T cell activation.[2]
Recognition
editIn 2014, Freeman received the William B. Coley Award along with Tasuku Honjo, Lieping Chen and Arlene Sharpe.[3]
In 2017, Freeman was one of the winners of the Warren Alpert Foundation Prize, and in 2022 he was elected to the American Academy of Arts and Sciences and the National Academy of Sciences.[4][5][6]
References
edit- ^ "Gordon J. Freeman, PhD, recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology | Dana-Farber Cancer Institute". www.dana-farber.org. Retrieved 4 March 2024.
- ^ "Gordon J. Freeman, Ph.D." Science. Retrieved 4 March 2024.
- ^ "Gordon J. Freeman, PhD". American Association for Cancer Research (AACR). Retrieved 4 March 2024.
- ^ "Gordon Freeman | Warren Alpert Foundation Prize". warrenalpert.org. Retrieved 4 March 2024.
- ^ "Gordon Freeman". www.nasonline.org. Retrieved 4 March 2024.
- ^ "Gordon J. Freeman". American Academy of Arts & Sciences. 4 March 2024.